12/2
03:41 pm
cue
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:49 pm
cue
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
01:30 pm
cue
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments [Yahoo! Finance]
High
Report
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments [Yahoo! Finance]
11/13
01:10 pm
cue
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments
Medium
Report
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments
11/13
01:09 am
cue
Cue Biopharma GAAP EPS of -$0.07 beats by $0.02, revenue of $2.15M misses by $0.14M [Seeking Alpha]
Medium
Report
Cue Biopharma GAAP EPS of -$0.07 beats by $0.02, revenue of $2.15M misses by $0.14M [Seeking Alpha]
11/12
04:53 pm
cue
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
High
Report
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/12
04:05 pm
cue
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Medium
Report
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/6
08:00 am
cue
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
Medium
Report
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
9/29
09:30 am
cue
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates [Yahoo! Finance]
Low
Report
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates [Yahoo! Finance]
9/29
09:00 am
cue
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
Low
Report
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates